CIRB Studies
Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number | Lead Group | Study Title | CIRB | Study Status |
|---|---|---|---|---|
| NRG-BN001 | NRG | Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma | Adult CIRB - Late Phase Emphasis | Available to Open |
| NSABP-B-55 | NSABP | A Randomised; Double-blind; Parallel group; Placebo-controlled Multi-centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy | Adult CIRB - Late Phase Emphasis | Available to Open |
| NHSR10.2021 | NCI | 21st Century Cures Act and PRA Implementation | Adult CIRB - Late Phase Emphasis | Completed |
| EA9171 | Alliance | BLAST MRD CML 1 Trial: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MRD) in Chronic Myeloid Leukemia (CML)- A Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with CML and Persistently Detectable MRD | Adult CIRB - Late Phase Emphasis | Available to Open |
| A011502 | Alliance | A Randomized Phase III Double Blinded Placebo-Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial | Adult CIRB - Late Phase Emphasis | Available to Open |
| S1609 | SWOG | DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors | Adult CIRB - Late Phase Emphasis | Available to Open |
| A071601 | Alliance | Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas | Adult CIRB - Late Phase Emphasis | Available to Open |
| NRG-GU007 | NRG | Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (with Initial Phase I) | Adult CIRB - Late Phase Emphasis | Available to Open |
| EA5182 | ECOG-ACRIN | Randomized Phase III Study of Combination AZD9291 (osimertinib) and Bevacizumab versus AZD9291 (osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) | Adult CIRB - Late Phase Emphasis | Available to Open |
| E1A06 | ECOG | An Intergroup Phase III Randomized Controlled Trial Comparing Melphalan; Prednisone and Thalidomide (MPT) Versus Melphalan; Prednisone and Lenalidomide (Revlimid TM) (MPR) in Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for High-Dose Therapy | Adult CIRB - Late Phase Emphasis | Available to Open |